Dual-Action Nanotherapy Targets Lung Cancer and Deadly Muscle-Wasting Syndrome in Single Dose

New lipid nanoparticle technique targets lung tumors to deliver follistatin mRNA, shrinking cancer while simultaneously reversing deadly muscle-wasting cachexia.

By: AXL Media

Published: Apr 7, 2026, 6:08 AM EDT

Source: Information for this report was sourced from Oregon State University.

Solving the Liver Accumulation Challenge One of the primary hurdles in mRNA therapy is the "liver trap." Standard lipid nanoparticles—the same delivery system used in many modern vaccines—often accumulate in the liver when injected into the bloodstream, limiting their effectiveness for other organs. The team at OSU College of Pharmacy, led by Oleh Taratula and Yoon Tae Goo, overcame this by utilizing a protein called vitronectin.

These engineered LNPs bind to vitronectin naturally found in the blood. Once bound, the protein acts as a GPS, navigating the particles to lung tumors by latching onto integrin receptors that are uniquely overexpressed on the surface of cancer cells. This "endogenous targeting" achieved a 2.5-fold greater reduction in tumor burden compared to conventional LNPs.

The Dual Role of Follistatin The researchers loaded these nanocarriers with follistatin messenger RNA (mRNA). Once the mRNA reaches the tumor, it instructs the cells to produce the follistatin protein. This protein serves two critical functions:

Antitumor Activity: It inhibits the growth and spread of lung cancer cells.

Muscle Preservation: It promotes muscle tissue growth, directly countering the effects of cachexia.

Addressing the Silent Killer: Cachexia Lung cancer remains the leading cause of cancer death in the United States, but it is often the secondary condition, cachexia, that proves fatal. Cachexia is a metabolic syndrome that causes the body to waste away, consuming muscle mass even when a patient maintains a high-calorie intake. It is estimated to kill as many as 30% of the cancer patients it affects.